1 In this double-blind, placebo controlled, prospective study, it was assessed whether simvastatin or pravastatin monotherapy have adverse effects on muscle histology and muscle membrane permeability in hypercholesterolaemic patients. 2 Twenty-four patients, seven females and 17 males, with primary hypercholesterolaemia (LDL cholesterol levels >4.14 mmol l-1) were selected from the outpatient lipid clinic of a 650 bed academic medical centre. 3 After a 6-week lipid lowering diet and placebo period, patients were randomized into two groups of 12 subjects with similar characteristics, to receive either simvastatin or pravastatin in dosages of 10-40 mg day-' for three periods of 6 weeks.
Introduction
Inhibitors of the rate limiting enzyme in the severe rhabdomyolysis: Lovastatin is associated with cholesterol-synthesis, 3-hydroxy-3-methylglutaryl-elevations of CK serum levels without symptoms in coenzyme A (HMG-CoA) reductase, have gained an 11% of the patients [1] . These CK elevations seem to important place in the treatment of hypercholesterol-be dose related and associated with physical exercise aemia. Although these drugs have been proven [1, 2] . Myopathy, defined as muscle tenderness comrelatively safe so far, adverse effects on skeletal bined with CK levels elevated more than 10 times the muscles have been described, ranging from asympto-upper limit of normal (ULN), is reported in 0.1 to 0.2 matic elevations of serum creatine kinase (CK) When lovastatin is combined with gemfibrozil, the incidence of myopathy is 5-30% [6] [7] [8] [9] . Rhabdomyolysis has been reported in combinations of lovastatin with erythromycin, niacin or cyclosporin [3, [10] [11] [12] [13] . Simvastatin, a more powerful HMG-CoA reductase inhibitor than lovastatin, is associated with elevations of CK and myopathy as well [14] [15] [16] [17] . Pravastatin, which has been claimed to cause less adverse reactions due to its hydrophylicity, has nevertheless also been associated with elevations of CK and myopathy [18, 19] . Since treatment with these drugs should be continued lifelong, it is important to study the relation between HMG-CoA reductase inhibitors and muscle pathology and to see whether there are differences between two statins which differ in water/lipid solubility. In this study, muscle damage is determined by assessing the release of the muscle proteins CK and myoglobin (Mb) following a lean body mass (LBM) standardized exercise provocation test in 24 hypercholesterolaemic patients before and during treatment with simvastatin or pravastatin. This test is based on the fact that the exercise induced release of CK and Mb is more pronounced in subjects with (subclinical) muscular pathology than in normals [20] [21] [22] [23] . Furthermore, muscle biopsies to detect histologic alterations under HMG-CoA reductase inhibition are obtained.
Methods

Patients
Twenty-four patients with primary hypercholesterolaemia, 17 men and seven women, age 51 ± 8 years, having low-density lipoprotein (LDL) cholesterol levels .4.65 mmol 1-1 and triglycerides (TG) < 4.6 mmol 1-l, were selected from recently diagnosed hypercholesterolaemic patients from the Lipid Clinic of the University Hospital Utrecht. Patients with diabetes mellitus, renal, hepatic, muscle or cardiac diseases were excluded. Diseases or drug-therapy, known to be accompanied with elevated CK or Mb levels were excluded as well. Before entering the study, informed consent was obtained from all patients.
Study protocol
The study protocol was approved by the Medical Ethics Committee of the University Hospital Utrecht. The patients entered a dietary baseline period of 6 weeks. They were instructed by a dietician and consumed a standard lipid lowering diet containing 50% of calories from carbohydrates, 20% from proteins, 30% from fat with a polyunsaturated-/saturated lipid ratio of 1. Daily intake of cholesterol was <300 mg. During this 6-week period, the patients received two placebo-tablets each evening; one resembling simvastatin 10 mg, the other resembling pravastatin 10 mg.
At the end of the 6-week baseline period, total cholesterol (TC), high-density lipoprotein (HDL) cholesterol and TG levels were determined. LDL cholesterol was calculated using the Friedewald formula [24] . Patients with LDL cholesterol >4.14 mmol 1-l were randomized into two treatment groups; one to be treated with simvastatin, the other to be treated with pravastatin. The active treatment phase consisted of three successive periods of 6 weeks. At the end of each period, fasting lipid levels and safety parameters were measured. Patients were interviewed for tolerability and adverse events. A physical examination was performed after each treatment period. Dietary adherence was evaluated and a tablet count was performed to assess drug compliance. The attainment of an equipotent dosage regime of simvastatin or pravastatin was attempted in the following manner. In the simvastatin treatment group, patients were treated with 10 mg simvastatin in the evening and pravastatin placebo. In the pravastatin group, patients started with 10 mg pravastatin in the evening and simvastatin placebo. If at the end of the first 6 [22, 23] . This is a 45 min long exercise-performance test on a bicycle ergometer, load 2 watt kg-' lean body mass (total body weight minus body fat content). Body fat content was estimated by measurement of biceps-, triceps-, subscapular-and suprapelvic skin folds. Heart frequency was registered very 5 min and kept below the value calculated by 220 minus age in years. Work load was registered every 5 min and reduced if necessary. During the second exercise test (in the last week of the active treatment period), work load was kept identical to the work load during the first test for each individual. The patients were told to avoid strenuous exercise during 24 h before the test. Blood samples for CK and Mb analysis were taken before the exercise test as well as 1 and 8 h after the test. It was demonstrated before that peak CK levels occur 8 h after the test whereas peak Mb are observed 1 h after exercise [20] [21] [22] [23] 25] . The exercise induced muscle damage is reflected by the maximal rise in CK and Mb levels after exercise (i.e. the difference between post-exercise peak CK and Mb levels and pre-exercise levels) [20, 22, 23, 25] .
Muscle biopsy Forty-eight hours after both exercise tests, the patients underwent a muscle biopsy. After local anaesthesia with Marcaine® 0.5%, a disposable biopsy needle (Travenol Tru-Cut®, 14 Ga, 15 [28] . In all tests a P value of less than 0.05 was considered significant.
Results
Two patients could not be analysed of the 24 patients who entered the study. One patient in the simvastatin group could not perform the second ergometer test because of angina pectoris, the other patient discontinued the study for personal reasons, unrelated to the drug used. The pravastatin and simvastatin treatment groups at the end of the baseline period were identical with regards to age, gender and lipid parameters ( Table 1) . Results of the first exercise test, before Muscle biopsies Muscle biopsy was not successful in two patients at the end of the baseline period, one in the simvastatin and one in the pravastatin treatment groups. The results of the other muscle biopsies are given in Table 4 . Agreement between the observers was fair to moderate/substantial [28] . No differences in muscle histology were found, between the two series of biopsies, within either treatment group and between the two groups for both tests. Three muscle biopsies at the end of the placebo period and four after active treatment were classified m  70  3  15  42  2  -13  75  3  3  47  5  6  40  2  m  74  8  5  26  3  -6  51  4  11  33  0  -4  40  3  m  184  11  165  76  33  -9  98  15  99  34  22  5  40  4  m  180  17  14  22  22  6  263 -20  20  32  21  20  40  5  m   63  37  119  32  213  3  54  23  48  26  83  7  20  6  m  44  11  33  21  23  31  53  24  19  30  6  7  20  7  m  126  0  10  40  4  11  108  0  29  32  7  9 'abnormal' in the pravastatin group. No patient had an abnormal histology after placebo and one after active treatment in the simvastatin group. There was no relation between absolute pre-exercise levels of CK or Mb or rise of muscle proteins after exercise and histologic classification.
Discussion
The goal of this study was to determine the relation between monotherapy with the HMG-CoA reductase inhibitors simvastatin and pravastatin and muscle pathology. Reust et al. studied CK levels after exercise in healthy volunteers on lovastatin and placebo and did not find any differences between the two groups [29] . In this study, we determined not only CK but Mb as well, since Mb is a more sensitive parameter for muscular pathology after exercise than CK [22, 23, 25, 30] . No differences between preexercise absolute CK and Mb and CK and Mb rises were found between the first and second exercise within both groups and between the simvastatin and pravastatin group. Taken the number of subjects participating in this study, the observed standard deviations in the exercise induced rise between first and second exercise test and a power of 0.8, it could be calculated that the differences in maximal CK rise (observed 8 h after exercise) between first and second exercise tests had to be 35 u 1-l for the simvastatin group and 38 u 1-l for the pravastatin group to reach significance. For Mb rise, 1 h after exercise, these levels were 45 ng dl-1 for the simvastatin group and 22 ng dl-1 for the pravastatin group. In studies on exercise induced muscle protein rise in subjects with subclinical muscle disease, differences in CK and Mb rise between subjects and healthy controls were observed beyond these significance thresholds, and although the pathogenesis of these diseases might differ from statin related myopathy, the number of subjects participating in the present study is sufficient to detect differences in CK and Mb rise that even fall below the values found in other diseases [2-5, 20, 21, 23] . It is striking that absolute pre-exercise CK levels before the first exercise test were elevated in some subjects. This could not be attributed to factors known to be accompanied by elevations of CK. One could wonder if hypercholesterolaemia in itself is associated with muscle damage [31] . We con- [3, [10] [11] [12] [13] 33] . One could expect differences between pravastatin and simvastatin in adverse systemic effects, due to the fact that pravastatin is hydrophilic and simvastatin is not [18, 33] . These characteristics however were determined in vitro only and in assessing systemic adverse effects the influences of drug metabolism have to be taken into account: e.g. the hepatic extraction ratio of simvastatin is larger than that of pravastatin and metabolites of both drugs might or might not have systemic effects as well [35] [36] [37] [38] . Indeed, it would be interesting to determine bound and unbound plasma levels of these drugs. The lipid lowering effects of the two drugs are in agreement with the literature [18, 35, 39] . In conclusion, we did not find evidence for muscular pathology after short-term (18 weeks) treatment with the HMG-CoA reductase inhibitors simvastatin or pravastatin, neither by studying the exercise induced release of CK and Mb, nor by histologic examination of muscle biopsies. The question whether long term treatment with HMG-CoA reductase inhibitors might reveal evidence for muscle damage remains to be studied.
